21 15) Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations. Esmee I.M.L. Liem, Hans Crezee, Jean J. de la Rosette & Theo M. de Reijke: International Journal of Hyperthermia ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal 16) BWT – UniThermia. https://www.elmedical-group.com 17) Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer. Richmond A. Owusu, Michael R. Abern, and Brant A. Inman : Biomed Res Int. 2013; 2013: 262313. 18) Intravesical device-assisted therapies for non-muscleinvasive bladder cancer. Wei Shen Tan & John D. Kelly: Nature Reviews Urology volume 15, pages667–685 (2018) 19) A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer. J. W. Van Hattum, E. M. Scutigliani, R. F. C. P. A. Helderman, R. Zweije, H. M. Rodermond, A. L. Oei,J. Crezee, J. R. Oddens, T. M. De Reijke & P. M. Krawczyk: Scientic Reports volume 12, Article number: 7017 (2022) 20) SYNERGO® FOR THE TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER. https://www.synergo-medical.com 21) Enhanced permeability of the urinary bladder wall: the role of polymer charge. M. Kerec Kos, M. Bogataj, A. Mrhar: Pharmazie 64: 232–237 (2009) 22) Thermal dosimetry for bladder hyperthermia treatment. An overview. Gerben Schooneveldt, Akke Bakker, Edmond Balidemaj, Rajiv Chopra, Johannes Crezee, Elisabeth D. Geijsen, Josen Hartmann, Maarten C.C.M. Hulshof, H. Petra Kok, Margarethus M. Paulides, Alejandro SousaEscandon, Paul R. Stauffer & Paolo F. Maccarini To cite this article: Gerben Schooneveldt, Akke Bakker, Edmond Balidemaj, Rajiv Chopra, Johannes Crezee, Elisabeth D. Geijsen, Josen Hartmann, Maarten C.C.M. Hulshof, H. Petra Kok, Margarethus M. Paulides, Alejandro SousaEscandon, Paul R. Stauffer & Paolo F. Maccarini (2016) International Journal of Hyperthermia, 32:4, 417-433 23) The effect of thermochemotherapy with mitomycin C on normal bladder urothelium, an experimental study. Murat Uçar, Muammer Altok, Mehmet Umul, Dilek Bayram: January 2016 International Urology and Nephrology 48(1) 24) Mitomycin C for the treatment of bladder cancer. A Volpe 1, M Racioppi, D D'Agostino, E Cappa, A Filianoti, P F Bassi: Minerva Urol Nefrol. 2010 Jun;62(2):133-44. 25) Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of supercial transitional cell carcinoma. Rita Paroni, Andrea Salonia, Avigdor Lev, Luigi Filippo Da Pozzo, Giuliana Cighetti, Francesco Montorsi, Patrizio Rigatti, and Renzo Colombo: Br J Clin Pharmacol. 2001 Sep; 52(3): 273–278. 26) Bladder wall penetration of intravesical mitomycin C in dogs. M G Wientjes 1, J T Dalton, R A Badalament, J R Drago, J L Au: Cancer Res . 1991 Aug 15;51(16):4347-54. 27) A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer. J. W.Van Hattum, E. M. Scutigliani, R. F. C. P.A. Helderman, R. Zweije , H. M. Rodermond, A. L. Oei, J. Crezee , J. R. Oddens, T. M. De Reijke1 & P. M. Krawczyk: www.nature.com/scienticreports 28) Clinical validation of a novel thermophysical bladder model designed to improve the accuracy of hyperthermia treatment planning in the pelvic region. Gerben Schooneveldt, H. Petra Kok, Akke Bakker, Elisabeth D. Geijsen, Coen R. N. Rasch, Jean J. M. C. H. de la Rosette: International Journal of Hyperthermia Volume 35, 2018 - Issue 1 Pages 383-397 29) Overview of bladder heating technology: matching capabilities with clinical requirements. Paul R. Stauffer, Gerard C. van Rhoon: Thomas Jefferson University; Department of Radiation Oncology Faculty Papers Department of Radiation Oncology 3-4-2016 30) The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. R. Lammers, J. Witjes: European urology Published 1 July 2011 31) Salvage Hyperthermic Gemcitabine and Docetaxel Combination Chemotherapy After BCG Failure in NonMuscle Invasive Bladder Cancer Patients. Rao, Mounica Y. | Kang, Paul | Tarajkowski, Jamaka C. | Mobley, Debra L. | Lamm, Donald L. Bladder Cancer, vol. 6, no. 1, pp. 2532, 2020 32) Intravesical chemotherapy in non-muscle-invasive bladder cancer. Sima P. Porten, Michael S. Leapman, and Kirsten L. Greene: Indian J Urol. 2015 Oct-Dec; 31(4): 297–303. 33) Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. Guido Dalbagni 1, Paul Russo, Joel Sheinfeld, Madhu Mazumdar, William Tong, Farhang Rabbani, Machelle S Donat, Harry W Herr, Pramod Sogani, Dominique dePalma, Dean Bajorin: J Clin Oncol. 2002 Aug 1;20(15):3193-8. 34) Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer. Richmond A. Owusu, Michael R. Abern, and Brant A. Inman: Biomed Res Int. 2013; 2013: 262313. 35) Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer. Steinberg, Ryan L. Thomas, Lewis J. O’Donnell, Michael A.: Bladder Cancer, vol. 1, no. 1, pp. 65-72 36) The impact of O2 availability on human cancer. Jessica A. Bertout, Shetal A. Patel, and M. Celeste Simon: Nat Rev Cancer. 2008 Dec; 8(12): 967–975. UROLOGY, URO-ONCOLOGY AND SEXOLOGY UPDATE
RkJQdWJsaXNoZXIy NTIyOTQ=